• 1
    Aso Y, Akaza H, Kameyama S, Niijima T. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. In: Therapeutic progress in urological cancers. New York: Alan R. Liss, 1989: 38391.
  • 2
    Akaza H, Kameyama S, Kakizoe T, Koiso K, Aso Y, Niijima T. Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Jap J Urol 1992; 83: 1839.
  • 3
    Brosman SA. The use of bacillus Calmette-Guérin in the therapy of bladder carcinoma in situ. J Urol 1985; 134: 369.
  • 4
    Lamm DL, Thor DE, Stogdill VD, Radwin HM. Bladder cancer immunotherapy. J. Urol 1982; 128: 9315.
  • 5
    Tokunaga T, Kataoka T, Nakamura RM, Yamamoto S, Akagawa KS. Mode of antitumor action of BCG. Gann Monograph on Cancer Research. Tokyo: Japanese Association of Cancer Research, 1978; 21: 5972.
  • 6
    Lamm DL, Sarosdy MS, DeHaven JI. Percutaneous, oral, or intravesical BCG administration: what is the optimal route? EORTC Genitourinary Group Monograph 6: BCG in superficial bladder cancer. Alan R. Liss, 1989: 30110.
  • 7
    Ratliff TL, Kavoussi LR, Catalona WJ. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol 1988; 139: 4104.
  • 8
    Kuroda K, Ratliff TL. Functional characterization of the internalization of bacillus Calmette-Guérin by bladder tumor cells [abstract]. J Urol 1991; 145: 226.
  • 9
    Akaza H, Crabtree WN, Matheny RB JR, Soloway MS. Chemoimmunotherapy of implanted murine bladder cancer. Urology 1983; 21: 2736.
  • 10
    Dubos RJ. Rapid and submerged growth of mycobacteria in liquid media. Proc Soc Exp Biol Med 1945; 58: 36170.
  • 11
    Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 1987; 137: 1558.
  • 12
    Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local bacillees Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144: 538.
  • 13
    Böhle A, Nowc CH, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, et al. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 1990; 144: 5964.
  • 14
    Hudson MA, Ritchy JK, Catalona WJ, Brown EJ, Ratliff TL. Comparison of the fibronection-binding ability and antitumor efficacy of various mycobacteria. Cancer Res 1990; 50: 38437.
  • 15
    Mackaness GB, Auclair DJ, Lagrange PH. Immunopotentiation with BCG: I. immune response to different strains and preparations. J Natl Cancer Inst 1973; 51: 165567.
  • 16
    Morales A. Long-term results and complications of intracavitary bacillus Calmette-Guérin therapy for bladder cancer. J Urol 1984; 132: 4579.